Skip to main content

Following this conversion election in late December 2017, 94% of the outstanding bonds have now been redeemed, leaving only €0.8 million remaining Bonds.
 

“Since re-acquiring the rights to RUCONEST® we have built a self-sustaining and independent sales led pharmaceutical business, which is now profitable and cash generative."

- Dr Sijmen de Vries, Pharming's CEO
Cookies: This website uses cookies Check the cookies page for more information Accept Decline